Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 800 of 3499 entries
View as:

Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01725191 Org: User:
Start: 10/31/12 End: 05/31/15 Due: 05/31/16

Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00363779 Org: User:
Start: 06/30/06 End: 11/30/10 Due: 11/30/11

Oxaliplatin and Topotecan in Advance Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00313612 Org: User:
Start: 01/31/06 End: 12/31/12 Due: 12/31/13

Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00039117 Org: User:
Start: 04/30/02 End: - Due: -

Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02099136 Org: User:
Start: 09/30/99 End: 12/31/04 Due: 12/31/05

Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00072150 Org: User:
Start: 10/31/03 End: - Due: -

Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00408902 Org: User:
Start: 11/30/06 End: 12/31/08 Due: 12/31/09

GW572016 to Treat Recurrent Malignant Brain Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00107003 Org: User:
Start: 03/30/05 End: 11/30/12 Due: 11/30/13

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02723864 Org: User:
Start: 08/09/17 End: 12/31/21 Due: 12/31/22

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00602641 Org: User:
Start: 02/29/08 End: 02/22/26 Due: 02/22/27

Ixabepilone in Treating Young Patients With Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00331643 Org: User:
Start: 04/30/06 End: 06/30/09 Due: 06/30/10

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01851408 Org: User:
Start: 04/30/06 End: 02/29/12 Due: 02/28/13

A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

Phase: N/A Priority: Normal
NCT ID: NCT00001805 Org: User:
Start: 03/31/99 End: 06/30/00 Due: 06/30/01

Study of Variation Over Time in the Oral Microbiome

Phase: N/A Priority: Normal
NCT ID: NCT02049398 Org: User:
Start: 01/28/14 End: 12/23/15 Due: 12/23/16

Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00262821 Org: User:
Start: 02/28/06 End: 08/31/10 Due: 08/31/11

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Phase: N/A Priority: Normal
NCT ID: NCT04197713 Org: User:
Start: 06/30/20 End: 09/30/25 Due: 09/30/26

FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00066638 Org: User:
Start: 06/30/03 End: 03/31/11 Due: 03/31/12

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT01055314 Org: User:
Start: 01/31/10 End: 06/30/16 Due: 06/30/17

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00416455 Org: User:
Start: 09/30/07 End: 07/16/16 Due: 07/16/17

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00365274 Org: User:
Start: 08/31/06 End: 05/31/10 Due: 05/31/11

Anidulafungin Versus Fluconazole in the Treatment of Candidemia

Phase: N/A Priority: Normal
NCT ID: NCT00058682 Org: User:
Start: 04/30/03 End: 01/31/05 Due: 01/31/06

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00803062 Org: User:
Start: 04/30/09 End: 02/28/13 Due: 02/28/14

Study of Health Effects of Cosmetic Breast Augmentation

Phase: N/A Priority: Normal
NCT ID: NCT00342953 Org: User:
Start: 01/10/03 End: 07/10/20 Due: 07/10/21

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00923845 Org: User:
Start: 03/01/08 End: 06/22/17 Due: 06/22/18

Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00077363 Org: User:
Start: 05/31/04 End: - Due: -